Drug Interactions between choline salicylate / magnesium salicylate and prasugrel

GENERALLY AVOID: Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding, ulceration) and bruising or bleeding.

MANAGEMENT: Concomitant use of more than one salicylate at a time should generally be avoided. Patients treated with a salicylate should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.

MONITOR: Concomitant use of prasugrel with other agents that affect hemostasis including aspirin may increase the risk of bleeding. According to the product labeling, the effects of prasugrel on platelet aggregation were not significantly affected by aspirin 150 mg daily. However, bleeding time was increased compared with either drug alone. The safety of prasugrel during coadministration with other salicylates has not been established, but potentiation of gastrointestinal bleeding should be considered.

MANAGEMENT: Although prasugrel may be used with aspirin, caution is advised during coadministration with any salicylate, especially in patients at risk for gastrointestinal ulceration or bleeding. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, hematemesis, anorexia, and/or black, tarry stools.

MONITOR: Concomitant use of prasugrel with other agents that affect hemostasis including aspirin may increase the risk of bleeding. According to the product labeling, the effects of prasugrel on platelet aggregation were not significantly affected by aspirin 150 mg daily. However, bleeding time was increased compared with either drug alone. The safety of prasugrel during coadministration with other salicylates has not been established, but potentiation of gastrointestinal bleeding should be considered.

MANAGEMENT: Although prasugrel may be used with aspirin, caution is advised during coadministration with any salicylate, especially in patients at risk for gastrointestinal ulceration or bleeding. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, hematemesis, anorexia, and/or black, tarry stools.